Belgian biotech firm Novadip Biosciences has secured €10.4 million in a funding round led by US-based New Science Ventures. Existing investors, including Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq, and Invest.BW, also participated in the round. This capital brings the company's total convertible financing to €20 million since June 2025.
The new funds will support the pivotal Phase 3 clinical trial for NVD003, a treatment for congenital pseudarthrosis of the tibia. The trial is currently active in the United States and the European Union. Additionally, the company will use the capital to prepare a Biologics License Application for the US Food and Drug Administration.
Securing this investment unlocks a tranche of an €18 million venture debt agreement signed with the European Investment Bank in 2023. The company, which currently employs 53 people, has raised a total of €137 million in equity and non-dilutive funding since its founding in 2013.
Novadip aims to receive market authorization for NVD003 in pediatric cases by 2028, with plans to expand to adult bone defect treatments by 2031. If the FDA approves the license application, the company expects to qualify for a Rare Pediatric Disease Priority Review Voucher, which it estimates to be worth over $100 million.
